April 30, 2024Open Access

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Area-level measures of sociodemographic disadvantage may be associated with racial and ethnic disparities with respect to receipt of treatment for metastatic renal cell carcinoma (mRCC) but have not been investigated previously, to our knowledge.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Rahman et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6cbe9b6db6435876498f7 https://doi.org/https://doi.org/10.1001/jamanetworkopen.2024.8747

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Access to Health and Health Care: How Race and Ethnicity Matter2010 · 225 citations
2The Elixhauser Comorbidity Method Outperforms the Charlson Index in Predicting Inpatient Death After Orthopaedic Surgery2014 · 542 citations
3County-level Social Vulnerability is Associated With Worse Surgical Outcomes Especially Among Minority Patients2020 · 199 citations
4Minority Health Social Vulnerability Index and COVID-19 vaccination coverage — The United States, December 14, 2020–January 31, 20222023 · 18 citations
5Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era2016 · 41 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo